MLYS insider trading — Mineralys Therapeutics, Inc.
Over the last 90 days, insiders at Mineralys Therapeutics, Inc. (MLYS) made 0 open-market purchases worth $0 and 1 open-market sale worth $3.01M, making them net sellers by $3.01M. The largest sale was by Slingsby Brian Taylor (Director), who sold 104,320 shares for $3.01M on Sep 22, 2026.
Updated Oct 16, 2026.
Recent MLYS insider transactions
Every Form 4 filed by Mineralys Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Congleton Jon | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 75,000 | $25.46 | $1.91M | Form 4 |
| Sep 22, 2026 | Slingsby Brian Taylor | Director | S · Sale | Indirect | 104,320 | $28.81 | $3.01M | Form 4 |
| Sep 21, 2026 | Warren Eric | Chief Commercial Officer | M · Option exercise · 10b5-1 | Direct | 7,438 | $13.24 | $98K | Form 4 |
| Sep 21, 2026 | Warren Eric | Chief Commercial Officer | S · Sale · 10b5-1 | Direct | 7,438 | $28.12 | $209K | Form 4 |
| Sep 15, 2026 | Karydas Daphne | Director | M · Option exercise · 10b5-1 | Direct | 3,000 | $12.02 | $36K | Form 4 |
| Sep 15, 2026 | Karydas Daphne | Director | S · Sale · 10b5-1 | Direct | 3,000 | $28.58 | $86K | Form 4 |
| Aug 21, 2026 | Warren Eric | Chief Commercial Officer | M · Option exercise · 10b5-1 | Direct | 7,437 | $13.24 | $98K | Form 4 |
| Aug 21, 2026 | Warren Eric | Chief Commercial Officer | S · Sale · 10b5-1 | Direct | 7,437 | $25.98 | $193K | Form 4 |
| Aug 10, 2026 | Rodman David Malcom | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 2,170 | $16.00 | $35K | Form 4 |
| Aug 10, 2026 | Rodman David Malcom | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 2,170 | $27.09 | $59K | Form 4 |
| Aug 10, 2026 | Ferguson James J. Iii | Chief Medical Officer | A · Grant/award | Direct | 102,400 | — | — | Form 4 |
| Jul 21, 2026 | Warren Eric | Chief Commercial Officer | M · Option exercise · 10b5-1 | Direct | 7,438 | $13.24 | $98K | Form 4 |
| Jul 21, 2026 | Warren Eric | Chief Commercial Officer | S · Sale · 10b5-1 | Direct | 7,438 | $26.87 | $200K | Form 4 |
| Jul 17, 2026 | Rodman David Malcom | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 416 | $15.44 | $6K | Form 4 |
| Jul 17, 2026 | Rodman David Malcom | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 416 | $26.53 | $11K | Form 4 |
MLYS insider trading FAQ
Are insiders buying MLYS stock?
Not on the open market. In the last 90 days, Mineralys Therapeutics, Inc. insiders made no open-market purchases, and 1 open-market sale totaling $3.01M. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading MLYS?
Recent sellers: Slingsby Brian Taylor.
Where does MLYS insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.